<p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）在週四向投資者發佈的研究報告中，TD Cowen 分析師將其目標價格從 63.00 美元上調至 72.00 美元，Benzinga 報道。該公司目前對該股票給予 “買入” 評級。TD Cowen 的目標價格暗示該股票相較於之前的收盤價有 18.73% 的潛在上漲空間。</p>
<p>獲取 <strong>Guardant Health</strong> 警報：</p>
<ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
<p>其他研究分析師也對該股票發佈了報告。加拿大豐業銀行將 Guardant Health 的目標價格從 57.00 美元上調至 60.00 美元，並在 7 月 31 日的報告中給予該股票 “行業跑贏大盤” 評級。古根海姆將 Guardant Health 的目標價格從 56.00 美元上調至 67.00 美元，並在週四的研究報告中給予該股票 “買入” 評級。富國銀行在週一的研究報告中開始覆蓋 Guardant Health 的股票。他們給予 “增持” 評級，並設定 72.00 美元的目標價格。威廉·布萊爾在週四的研究報告中重申了對 Guardant Health 的 “跑贏大盤” 評級。最後，Cowen 在週四的研究報告中重新發布了對 Guardant Health 的 “買入” 評級。一位分析師對該股票給予了強烈買入評級，22 位分析師給予了買入評級。根據 MarketBeat.com 的數據，Guardant Health 目前的平均評級為 “買入”，共識目標價格為 64.75 美元。</p>
<p><strong>獲取我們對 Guardant Health 的最新股票分析</strong></p>
<h2>Guardant Health 股票表現</h2>
<ul>
<li>解讀顛覆：凱西·伍德最新投資策略</li>
</ul>
<p>在週四的午盤交易中，納斯達克：GH 上漲 2.97 美元，達到 60.64 美元。該股票交易量為 2,793,540 股，而其平均交易量為 2,400,886 股。該公司的 50 日移動平均線為 55.08 美元，200 日移動平均線為 48.55 美元。Guardant Health 的 12 個月低點為 20.14 美元，12 個月高點為 68.00 美元。該股票的市值為 75.6 億美元，市盈率為-17.99，貝塔值為 1.46。</p>
<p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）最近在 7 月 30 日發佈了季度財報。該公司報告季度每股收益（EPS）為-0.44 美元，超出市場共識預期的-0.52 美元，超出幅度為 0.08 美元。該公司在本季度的收入為 2.3209 億美元，而市場共識預期為 2.1119 億美元。去年同期，該公司每股收益為-0.84 美元。與去年同期相比，該季度的收入增長了 31.0%。Guardant Health 已將其 2025 財年的指導目標設定為每股收益。分析師平均預測 Guardant Health 在當前財年將發佈-2.9 的每股收益。</p>
<h2>Guardant Health 的內部買賣情況</h2>
<ul>
<li>3 只快速增長的股票分析師預計價格將翻倍</li>
</ul>
<p>在其他消息中，首席執行官 Helmy Eltoukhy 在 9 月 9 日的交易中出售了 300,000 股公司股票。股票以平均價格 59.45 美元出售，總價值為 17,835,000.00 美元。交易完成後，首席執行官直接持有公司 2,123,499 股，價值約為 126,242,015.55 美元。這代表其持股比例減少了 12.38%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，首席執行官 Amirali Talasaz 在 7 月 1 日的交易中出售了 100,000 股公司股票。該股票以平均價格 50.88 美元出售，總交易額為 5,088,000.00 美元。交易完成後，首席執行官持有公司 1,971,830 股，價值約為 100,326,710.40 美元。該交易使其持股比例減少了 4.83%。該銷售的披露信息可在此處找到。內部人士在上個季度出售了價值 23,069,965 美元的 402,691 股公司股票。內部人士持有公司 6.10% 的股份。</p>
<h2>Guardant Health 的機構交易情況</h2>
<p>對沖基金最近增加或減少了在該公司的持股。IFP Advisors Inc 在第二季度將其在 Guardant Health 的持股增加了 120.1%。IFP Advisors Inc 目前持有 612 股公司股票，價值 33,000 美元，此前在該期間內增持了 334 股。Signaturefd LLC 在第二季度將其在 Guardant Health 的持股增加了 50.5%。Signaturefd LLC 目前持有 635 股公司股票，價值 33,000 美元，此前在該期間內增持了 213 股。Allworth Financial LP 在第二季度將其在 Guardant Health 的持股增加了 358.4%。Allworth Financial LP 目前持有 706 股公司股票，價值 37,000 美元，此前在該期間內增持了 552 股。FNY Investment Advisers LLC 在第二季度獲得了 Guardant Health 的新頭寸，價值約為 62,000 美元。最後，SVB Wealth LLC 在第一季度獲得了 Guardant Health 的新頭寸，價值約為 54,000 美元。92.60% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Guardant Health 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Guardant Health, Inc 是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 響應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，這是一個為臨牀和生物製藥客户設計的集成軟件解決方案，旨在將接受檢測的患者與具有潛在相關臨牀研究的可操作性改變相連接；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，這是一個用於腫瘤演變和治療耐藥性研究的計算機模擬平台，適用於各種生物標誌物驅動的癌症。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而非 Guardant Health</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>Cintas 股票在動能增強時發出明確的買入信號</li>
<li>什麼是支撐位？</li>
<li>美光的股價反彈尚未結束：MU $190 即將到來</li>
<li>高股息房地產投資信託：它們是理想的多元化方式嗎？</li>
<li>為什麼交易者在大幅反彈後加倍押注 SoundHound 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
<p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Guardant Health 並不在名單上。</p>
<p>雖然 Guardant Health 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>TD Cowen 將 Guardant Health (NASDAQ:GH) 的目標股價從 63.00 美元上調至 72.00 美元，維持 “買入” 評級。這意味着相較於前一交易日收盤價有 18.73% 的上漲空間。其他分析師也提高了他們的目標價，蘇格蘭銀行將其設定為 60.00 美元，古根海姆則為 67.00 美元。Guardant Health 的股票交易價格為 60.64 美元，市值為 75.6 億美元。該公司報告了同比增長 31% 的收入，上一季度每股收益為（0.44 美元），超出預期。內部人士最近出售了部分股份，減少了他們的持股比例</p>

<p>Guardant Health (NASDAQ:GH - Get Free Report) had its price objective boosted by analysts at TD Cowen from $63.00 to $72.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock. TD Cowen's price objective suggests a potential upside of 18.73% from the stock's previous close.</p>
<div class="lb-trans"><p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）在週四向投資者發佈的研究報告中，TD Cowen 分析師將其目標價格從 63.00 美元上調至 72.00 美元，Benzinga 報道。該公司目前對該股票給予 “買入” 評級。TD Cowen 的目標價格暗示該股票相較於之前的收盤價有 18.73% 的潛在上漲空間。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Guardant Health</strong> 警報：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
</div><p>Other research analysts have also issued reports about the stock. Scotiabank upped their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the stock a &#34;sector outperform&#34; rating in a report on Thursday, July 31st. Guggenheim increased their price target on shares of Guardant Health from $56.00 to $67.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday. Wells Fargo &amp; Company assumed coverage on shares of Guardant Health in a research note on Monday. They issued an &#34;overweight&#34; rating and a $72.00 price target for the company. William Blair reiterated an &#34;outperform&#34; rating on shares of Guardant Health in a research note on Thursday. Finally, Cowen reissued a &#34;buy&#34; rating on shares of Guardant Health in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating and twenty-two have assigned a Buy rating to the stock. According to MarketBeat.com, Guardant Health presently has an average rating of &#34;Buy&#34; and a consensus target price of $64.75.</p>
<div class="lb-trans"><p>其他研究分析師也對該股票發佈了報告。加拿大豐業銀行將 Guardant Health 的目標價格從 57.00 美元上調至 60.00 美元，並在 7 月 31 日的報告中給予該股票 “行業跑贏大盤” 評級。古根海姆將 Guardant Health 的目標價格從 56.00 美元上調至 67.00 美元，並在週四的研究報告中給予該股票 “買入” 評級。富國銀行在週一的研究報告中開始覆蓋 Guardant Health 的股票。他們給予 “增持” 評級，並設定 72.00 美元的目標價格。威廉·布萊爾在週四的研究報告中重申了對 Guardant Health 的 “跑贏大盤” 評級。最後，Cowen 在週四的研究報告中重新發布了對 Guardant Health 的 “買入” 評級。一位分析師對該股票給予了強烈買入評級，22 位分析師給予了買入評級。根據 MarketBeat.com 的數據，Guardant Health 目前的平均評級為 “買入”，共識目標價格為 64.75 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Guardant Health 的最新股票分析</strong></p>
</div><h2>Guardant Health Stock Performance</h2>
<div class="lb-trans"><h2>Guardant Health 股票表現</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解讀顛覆：凱西·伍德最新投資策略</li>
</ul>
</div><p>NASDAQ:GH traded up $2.97 during midday trading on Thursday, reaching $60.64. 2,793,540 shares of the stock traded hands, compared to its average volume of 2,400,886. The company has a fifty day moving average of $55.08 and a 200 day moving average of $48.55. Guardant Health has a 12 month low of $20.14 and a 12 month high of $68.00. The stock has a market capitalization of $7.56 billion, a P/E ratio of -17.99 and a beta of 1.46.</p>
<div class="lb-trans"><p>在週四的午盤交易中，納斯達克：GH 上漲 2.97 美元，達到 60.64 美元。該股票交易量為 2,793,540 股，而其平均交易量為 2,400,886 股。該公司的 50 日移動平均線為 55.08 美元，200 日移動平均線為 48.55 美元。Guardant Health 的 12 個月低點為 20.14 美元，12 個月高點為 68.00 美元。該股票的市值為 75.6 億美元，市盈率為-17.99，貝塔值為 1.46。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the company posted ($0.84) earnings per share. The firm's revenue for the quarter was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, analysts predict that Guardant Health will post -2.9 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）最近在 7 月 30 日發佈了季度財報。該公司報告季度每股收益（EPS）為-0.44 美元，超出市場共識預期的-0.52 美元，超出幅度為 0.08 美元。該公司在本季度的收入為 2.3209 億美元，而市場共識預期為 2.1119 億美元。去年同期，該公司每股收益為-0.84 美元。與去年同期相比，該季度的收入增長了 31.0%。Guardant Health 已將其 2025 財年的指導目標設定為每股收益。分析師平均預測 Guardant Health 在當前財年將發佈-2.9 的每股收益。</p>
</div><h2>Insider Buying and Selling at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的內部買賣情況</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師預計價格將翻倍</li>
</ul>
</div><p>In other news, CEO Helmy Eltoukhy sold 300,000 shares of the company's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the completion of the transaction, the chief executive officer owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. The trade was a 4.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 402,691 shares of company stock worth $23,069,965 over the last quarter. Insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Helmy Eltoukhy 在 9 月 9 日的交易中出售了 300,000 股公司股票。股票以平均價格 59.45 美元出售，總價值為 17,835,000.00 美元。交易完成後，首席執行官直接持有公司 2,123,499 股，價值約為 126,242,015.55 美元。這代表其持股比例減少了 12.38%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，首席執行官 Amirali Talasaz 在 7 月 1 日的交易中出售了 100,000 股公司股票。該股票以平均價格 50.88 美元出售，總交易額為 5,088,000.00 美元。交易完成後，首席執行官持有公司 1,971,830 股，價值約為 100,326,710.40 美元。該交易使其持股比例減少了 4.83%。該銷售的披露信息可在此處找到。內部人士在上個季度出售了價值 23,069,965 美元的 402,691 股公司股票。內部人士持有公司 6.10% 的股份。</p>
</div><h2>Institutional Trading of Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的機構交易情況</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc lifted its stake in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after acquiring an additional 334 shares during the period. Signaturefd LLC increased its holdings in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after buying an additional 213 shares during the period. Allworth Financial LP increased its holdings in Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company's stock worth $37,000 after buying an additional 552 shares during the period. FNY Investment Advisers LLC acquired a new position in Guardant Health in the 2nd quarter worth approximately $62,000. Finally, SVB Wealth LLC acquired a new position in Guardant Health in the 1st quarter worth approximately $54,000. 92.60% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近增加或減少了在該公司的持股。IFP Advisors Inc 在第二季度將其在 Guardant Health 的持股增加了 120.1%。IFP Advisors Inc 目前持有 612 股公司股票，價值 33,000 美元，此前在該期間內增持了 334 股。Signaturefd LLC 在第二季度將其在 Guardant Health 的持股增加了 50.5%。Signaturefd LLC 目前持有 635 股公司股票，價值 33,000 美元，此前在該期間內增持了 213 股。Allworth Financial LP 在第二季度將其在 Guardant Health 的持股增加了 358.4%。Allworth Financial LP 目前持有 706 股公司股票，價值 37,000 美元，此前在該期間內增持了 552 股。FNY Investment Advisers LLC 在第二季度獲得了 Guardant Health 的新頭寸，價值約為 62,000 美元。最後，SVB Wealth LLC 在第一季度獲得了 Guardant Health 的新頭寸，價值約為 54,000 美元。92.60% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 響應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，這是一個為臨牀和生物製藥客户設計的集成軟件解決方案，旨在將接受檢測的患者與具有潛在相關臨牀研究的可操作性改變相連接；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，這是一個用於腫瘤演變和治療耐藥性研究的計算機模擬平台，適用於各種生物標誌物驅動的癌症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Cintas Stock Sends a Clear Buy Signal as Momentum Builds</li>
<li>What is a support level?</li>
<li>Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Why Traders Are Doubling Down on SoundHound Stock After Big Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Guardant Health</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>Cintas 股票在動能增強時發出明確的買入信號</li>
<li>什麼是支撐位？</li>
<li>美光的股價反彈尚未結束：MU $190 即將到來</li>
<li>高股息房地產投資信託：它們是理想的多元化方式嗎？</li>
<li>為什麼交易者在大幅反彈後加倍押注 SoundHound 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Guardant Health 並不在名單上。</p>
</div><p>While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Guardant Health 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

TD Cowen 將 Guardant Health（納斯達克代碼：GH）的目標股價上調至 72.00 美元